Biopharmaceutical CMO and CRO Market Size & Share Analysis - Growth Trends and Forecasts (2025 - 2030)

The Biopharmaceutical CMO and CRO Market Report is Segmented by Source (Mammalian and Non-Mammalian), Service Type (Contract Manufacturing and Contract Research), Product (Biologics and Biosimilars), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers the Value (in USD) for the Above Segments.

Biopharmaceutical CMO and CRO Market Size & Share Analysis - Growth Trends and Forecasts (2025 - 2030)

Biopharmaceutical CMO And CRO Market Size

Biopharmaceutical CMO And CRO Market Summary
Study Period 2019 - 2030
Market Size (2025) USD 83.41 Billion
Market Size (2030) USD 115.35 Billion
CAGR (2025 - 2030) 6.70 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Biopharmaceutical CMO And CRO Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Biopharmaceutical CMO And CRO Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Biopharmaceutical CMO And CRO Market Analysis

The Biopharmaceutical CMO And CRO Market size is estimated at USD 83.41 billion in 2025, and is expected to reach USD 115.35 billion by 2030, at a CAGR of 6.7% during the forecast period (2025-2030).

The market is driven by factors such as growing investment by market players to expand the biopharmaceutical CMO facility, growing robust pharmaceutical pipeline, and increasing strategic activities by the market players such as collaboration and partnership.

Due to the rising trend of outsourcing in the biopharmaceutical industry, the global CMO/CRO market is experiencing significant growth. For instance, in November 2022, Baxter International Inc. unveiled a substantial USD 100 million expansion for its sterile fill and finish manufacturing facility in Halle (Halle Westfalen), Germany. The Halle facility is operated by BioPharma Solutions (BPS), a branch of Baxter that collaborates with renowned pharmaceutical and biotech companies to create and contract-manufacture drug products for injectable pharmaceuticals (parenteral).

Similarly, in June 2022, the Government of Quebec bestowed a loan of USD 18 million upon Jubilant Pharma Limited to facilitate the expansion of the contract manufacturing facility in Montreal. Moreover, in October 2022, Evonik unveiled the completion of an expansion worth EUR 36 million (USD 38.12 million) for its contract manufacturing facilities in the United States and Europe. At various Evonik production sites, cutting-edge technologies encompassing high-potency APIs, fermentation, mPEGs, and continuous processing were either integrated or improved. Thus, expanding these contract manufacturing services is likely to increase their adoption by pharmaceutical and medical device companies and is anticipated to boost market growth.

Moreover, market players are also adopting several strategies, such as mergers, acquisitions, and collaboration, which are expected to boost the biopharmaceutical CMO & CRO market growth over the forecast period. For instance, in November 2023, Ichor Life Sciences, a CRO and longevity biotechnology company, announced the launch of Ichor Clinical Trial Services. With the founding of Ichor Clinical, the company can now serve biotechnology and pharmaceutical clients from early preclinical studies through late-stage clinical trials and F-A approval.

Additionally, in July 2023, TransCure bioServices, a CRO specializing in humanized mouse models, formed a strategic partnership with Precl na Inc., based in South Korea, specializing in autoimmune and inflammatory diseases. This partnership is a significant milestone for TransCure as it expands its presence into the APAC region, strengthens its service portfolio, and enhances the quality of its research outcomes.

Hence, increasing funding for expanding manufacturing facilities and strategic initiatives taken by the CRO and CMO companies is expected to boost the market over the forecast period. However, limited outsourcing among well-established biopharmaceutical manufacturers and regulatory challenges are expected to restrain the market over the forecast period.

Biopharmaceutical CMO And CRO Industry Overview

The biopharmaceutical CMO and CRO market is moderately competitive and consists of several significant players. In terms of market share, a few major players dominate the market. Some prominent players are vigorously making acquisitions of other companies to consolidate their global market positions. Some of the major market players are Lonza Group AG, ICON PLC, Parexel International Corporation, Samsung Biologics, and Charles River Laboratories International Inc.

Biopharmaceutical CMO And CRO Market Leaders

  1. Lonza Group AG

  2. ICON Plc

  3. Parexel International Corporation

  4. Samsung Biologics

  5. Charles River Laboratories International, Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Biopharmaceutical CMO And CRO Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Biopharmaceutical CMO And CRO Market News

  • March 2024: FSD Pharma Inc. announced that through its subsidiary, HUGE Biopharma Australia Pty Ltd, it entered an agreement with iNGENu CRO Pty Ltd to conduct "A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants."
  • November 2023: Axxam SpA partnered with Momentum Biotechnologies, a CRO, to offer biotechnology and pharmaceutical clients with unique drug discovery solutions. The partnership will allow Momentum to use Axxam's highly curated chemical diversity library, which is made up of 325,000 compounds, for high-throughput screening using Momentum's mass spectrometry-based functional and binding assay platforms.

Biopharmaceutical CMO And CRO Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definitions
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Investment by CMOs For Capacity Expansion
    • 4.2.2 Robust Biopharmaceuticals Pipeline
    • 4.2.3 Cost And Time Saving Benefits Offered By Contract Services
  • 4.3 Market Restraints
    • 4.3.1 Limited Outsourcing Amongst Well-Stablished Biopharmaceutical Manufacturer
    • 4.3.2 Regulatory Challenges
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value – USD)

  • 5.1 By Source
    • 5.1.1 Mammalian
    • 5.1.2 Non-mammalian
  • 5.2 By Services Type
    • 5.2.1 Contract Manufacturing
    • 5.2.1.1 Process Development
    • 5.2.1.2 Fill & Finish Operations
    • 5.2.1.3 Analytical & QC Studies
    • 5.2.1.4 Packaging
    • 5.2.2 Contract Research
    • 5.2.2.1 Oncology
    • 5.2.2.2 Inflammation & Immunology
    • 5.2.2.3 Cardiology
    • 5.2.2.4 Neuroscience
    • 5.2.2.5 Others
  • 5.3 By Product
    • 5.3.1 Biologics
    • 5.3.1.1 Monoclonal antibodies (MAbs)
    • 5.3.1.2 Recombinant Proteins
    • 5.3.1.3 Vaccines
    • 5.3.1.4 Antisense, RNAi, & Molecular Therapy
    • 5.3.1.5 Others
    • 5.3.2 Biosimilars
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 United Kingdom
    • 5.4.2.2 Germany
    • 5.4.2.3 France
    • 5.4.2.4 Spain
    • 5.4.2.5 Italy
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 India
    • 5.4.3.2 Japan
    • 5.4.3.3 China
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of the Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Boehringer Ingelheim GmbH
    • 6.1.2 Lonza Group AG
    • 6.1.3 Inno Biologics Sdn Bhd
    • 6.1.4 Fujifilm Diosynth Biotechnologies U.S.A. Inc.
    • 6.1.5 Toyobo Co. Ltd
    • 6.1.6 Samsung Biologics
    • 6.1.7 Thermo Fisher Scientific Inc (Patheon & PPD)
    • 6.1.8 WuXi Biologics
    • 6.1.9 Charles River Laboratories International Inc.
    • 6.1.10 ICON PLC
    • 6.1.11 Parexel International Corporation
    • 6.1.12 Laboratory Corporation of America Holdings
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Biopharmaceutical CMO And CRO Industry Segmentation

As per the scope of the report, biopharmaceutical CMO (contract manufacturing organization) refers to companies that provide manufacturing services to biopharmaceutical companies. They handle the production of drugs, biologics, or other pharmaceutical products on a contractual basis.

The biopharmaceutical CMO and CRO market is segmented by source, service type, contract research, products, and geography. By source, the market is segmented as mammalian and non-mammalian. The market is segmented by service type as contract manufacturing (process development, fill and finish operations, analytical & qc studies, and packaging). The market is segmented by contract research as oncology, inflammation & immunology, cardiology, neuroscience, and others. The market is segmented by product as biologics and biosimilars; by geography, the market is segmented as North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (in USD) for the above segments.

By Source Mammalian
Non-mammalian
By Services Type Contract Manufacturing Process Development
Fill & Finish Operations
Analytical & QC Studies
Packaging
Contract Research Oncology
Inflammation & Immunology
Cardiology
Neuroscience
Others
By Product Biologics Monoclonal antibodies (MAbs)
Recombinant Proteins
Vaccines
Antisense, RNAi, & Molecular Therapy
Others
Biosimilars
Geography North America United States
Canada
Mexico
Europe United Kingdom
Germany
France
Spain
Italy
Rest of Europe
Asia-Pacific India
Japan
China
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of the Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Biopharmaceutical CMO And CRO Market Research FAQs

How big is the Biopharmaceutical CMO And CRO Market?

The Biopharmaceutical CMO And CRO Market size is expected to reach USD 83.41 billion in 2025 and grow at a CAGR of 6.70% to reach USD 115.35 billion by 2030.

What is the current Biopharmaceutical CMO And CRO Market size?

In 2025, the Biopharmaceutical CMO And CRO Market size is expected to reach USD 83.41 billion.

Who are the key players in Biopharmaceutical CMO And CRO Market?

Lonza Group AG, ICON Plc, Parexel International Corporation, Samsung Biologics and Charles River Laboratories International, Inc. are the major companies operating in the Biopharmaceutical CMO And CRO Market.

Which is the fastest growing region in Biopharmaceutical CMO And CRO Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Biopharmaceutical CMO And CRO Market?

In 2025, the North America accounts for the largest market share in Biopharmaceutical CMO And CRO Market.

What years does this Biopharmaceutical CMO And CRO Market cover, and what was the market size in 2024?

In 2024, the Biopharmaceutical CMO And CRO Market size was estimated at USD 77.82 billion. The report covers the Biopharmaceutical CMO And CRO Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Biopharmaceutical CMO And CRO Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Biopharmaceutical CMO And CRO Industry Report

Statistics for the 2025 Biopharmaceutical CMO And CRO market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Biopharmaceutical CMO And CRO analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.